Pipeline
Advancing novel therapeutics and scalable, reliable and sustainable biomanufacturing of those therapeutics from discovery into the clinic.
Therapeutics
Our therapeutic programs leverage site-specific incorporation of non-canonical amino acids to create next-generation peptides and proteins with enhanced properties.
Our platform enables precise, site-specific modifications that create therapeutics with properties impossible to achieve through traditional methods: new functionalities, better stability, improved pharmacokinetics, and reduced immunogenicity.
Partner with usNext-generation GLP-1 receptor agonists with enhanced stability, improved pharmacokinetics, and reduced immunogenicity for metabolic disease treatment.
Peptides with non-canonical amino acids for enhanced stability, protease resistance, and improved pharmacokinetic properties.
Site-specific conjugation eliminates heterogeneity, providing optimal drug-antibody ratios for improved therapeutic windows and reduced toxicity.
Immunotherapy proteins with site-specific modifications for targeted delivery and enhanced immune activation with reduced systemic toxicity.
Next-generation antibody fragments with enhanced stability and novel chemical functionalities for challenging targets.
Modular assemblies combining antibodies with cytokines through click chemistry for dual-mechanism tumor targeting.
Peptides engineered for oral bioavailability with protease-resistant ncAAs enabling gastrointestinal stability and enhanced absorption for oral delivery.
Site-specific antigen-adjuvant conjugation through ncAA chemistry for enhanced immunogenicity, improved stability, and consistent vaccine formulation.
Biomanufacturing
Enabling robust, reliable bioproduction with our phage-resistant Syn61 platform for industrial-scale manufacturing.
Our Syn61 chassis provides inherent resistance to bacteriophage contamination, a critical advantage for industrial biomanufacturing where phage infection can cause catastrophic production failures.
Partner with usPlatform advantages
Phage-resistant production
Syn61's recoded genome makes it naturally resistant to bacteriophage infection, eliminating a major cause of batch failures.
Biocontainment features
Engineered genetic safeguards prevent survival outside controlled environments, meeting regulatory requirements for GMO containment.
Process robustness
Consistent, predictable performance across production scales with reduced batch-to-batch variability.
Scalable manufacturing
Proven fermentation protocols that transfer reliably from lab to industrial scale production.
Why site-specific modifications matter
Traditional chemical conjugation creates heterogeneous mixtures with variable drug-to-antibody ratios, leading to inconsistent efficacy and increased toxicity. Site-specific modification ensures every molecule is identical.
Use case 1
Antibody-Drug Conjugates
The challenge
Traditional ADC conjugation creates mixtures with 0-8 drugs per antibody. This heterogeneity leads to:
- • Batch-to-batch variability
- • Inconsistent efficacy
- • Increased toxicity from over-loaded antibodies
The solution
Install click chemistry handles (e.g., azide or tetrazine) at precise positions for:
- ✓ Defined drug-antibody ratio (e.g., exactly 2 or 4 drugs)
- ✓ Reproducible manufacturing
- ✓ Optimal therapeutic window
CLINICAL IMPACT
Improved patient outcomes through consistent dosing and reduced side effects
Use case 2
Covalent biologics
The challenge
Most biologics bind reversibly, requiring sustained high concentrations. This leads to:
- • Frequent dosing requirements
- • Limited duration of action
- • Off-target effects from high systemic exposure
The solution
Install reactive warheads at specific positions adjacent to binding sites for:
- ✓ Irreversible covalent bond formation with target
- ✓ Prolonged pharmacological effect
- ✓ Reduced dosing frequency
CLINICAL IMPACT
Long-lasting therapeutic effect with lower systemic exposure and improved patient compliance
Partnership opportunities
We're actively seeking partners to advance our pipeline programs.
Discuss partnership →